Pharmaceutical composition for preventing or treating cancer

Patent metadata

Field	Value
Publication number	US-2024238287-A1
Application number	US-202318399675-A
Country	US
Kind code	A1
Filing date	Dec 28, 2023
Priority date	Jun 28, 2021
Publication date	Jul 18, 2024
Grant date	—

Abstract

The present invention relates to a method for prevention, alleviation, or treatment of cancer patients, especially epithelial mesenchymal transition (EMP)-subtype cancer patients. If PHGDH, SHMT and MTHFD2 inhibitors are co-administered to patients with cancer in which the expression level of a glutaminase (GLS) gene or a protein encoded thereby has increased, 1C metabolism is more effectively inhibited such that there is a synergistic effect on the inhibition of cancer cell proliferation in patients with refractory cancer that is difficult to treat because of recurrence, metastasis, and anticancer drug resistance, thereby enabling cancer to be very effectively treated. In addition, the expression level of the GLS gene or protein encoded thereby is measured so that information related to customized treatment methods from initial stages is provided to each patient and the success of treatment can be increased.

First claim

1 . A pharmaceutical composition for prevention of treatment of cancer comprising:
a compound or a pharmaceutically acceptable salts thereof for inhibiting expression of a glutaminase (GLS) gene; and an agent or a pharmaceutically acceptable salt thereof for inhibiting the expression of a gene selected from the group consisting of a Phosphoglycerate Dehydrogenase (PHGDH) gene, a SHMT (Serine hydroxymethyltransferase (SHMT) gene, and an MTHFD2 (Methylenetetrahydrofolate Dehydrogenase (NADP+ Dependent) 2 or MethenyltetrahydrofolateCyclohydrolase) gene, gene.

2 . The pharmaceutical composition of claim 1 , wherein the agent specifically binds to the mRNA of the gene and is selected from the group consisting of an miRNA, siRNA, shRNA and antisense oligonucleotide.

3 . The pharmaceutical composition of claim 1 , further comprising an anticancer agent.

4 . The pharmaceutical composition of claim 1 , wherein the cancer is an epithelial mesenchymal transition (EMT) subtype.

5 . The pharmaceutical composition of claim 1 , wherein the cancer is gastric cancer, thyroid cancer, parathyroid cancer, ovarian cancer, colorectal cancer, pancreatic cancer, liver cancer, breast cancer, cervical cancer, lung cancer, non-small cell lung cancer, prostate cancer, gallbladder cancer, biliary tract cancer, non-Hodgkin lymphoma, Hodgkin's lymphoma, blood cancer, bladder cancer, head cancer, uterine cancer, rectal cancer, brain tumor, cancer, esophageal cancer, small intestinal cancer, endocrine adenocarcinoma, renal cancer, soft tissue sarcoma, urethral cancer, penis cancer, The pharmaceutical composition of any one selected from the group consisting of renal cell carcinoma, renal pelvic carcinoma, central nerve system (CNS) tumor, primary CNS lymphoma, spinal cord tumor, brain glioma, and pituitary adenoma.

6 . A pharmaceutical composition for prevention of treatment of cancer comprising:
a compound or a pharmaceutically acceptable salts thereof for inhibiting a function of a protein expressed by glutaminase (GLS) gene; and an agent or a pharmaceutically acceptable salt thereof for inhibiting a function of a protein expressed by a gene selected from the group consisting of a PHGDH gene, an SHMT gene, and an MTHFD2.

7 . The pharmaceutical composition of claim 6 , wherein the compound of the agent is an inverse agonist, or an antagonist, antibody or an aptamer binding to the protein selectively.

8 . The pharmaceutical composition of claim 6 , further comprising an anticancer agent.

9 . The pharmaceutical composition of claim 6 , wherein the cancer is an epithelial mesenchymal transition (EMT) subtype.

10 . The pharmaceutical composition of claim 6 , wherein the cancer is gastric cancer, thyroid cancer, parathyroid cancer, ovarian cancer, colorectal cancer, pancreatic cancer, liver cancer, breast cancer, cervical cancer, lung cancer, non-small cell lung cancer, prostate cancer, gallbladder cancer, biliary tract cancer, non-Hodgkin lymphoma, Hodgkin's lymphoma, blood cancer, bladder cancer, head cancer, uterine cancer, rectal cancer, brain tumor, cancer, esophageal cancer, small intestinal cancer, endocrine adenocarcinoma, renal cancer, soft tissue sarcoma, urethral cancer, penis cancer, The pharmaceutical composition of any one selected from the group consisting of renal cell carcinoma, renal pelvic carcinoma, central nerve system (CNS) tumor, primary CNS lymphoma, spinal cord tumor, brain glioma, and pituitary adenoma.

11 . A method for providing information for treating a patient with an epithelial mesenchymal transition (EMT) subtype comprising:
measuring an expression levels of a GLS gene or a protein encoded by it in a biological sample isolated from the object of interest; and if the expression level of the gene or protein measured above is elevated, determining to concomitantly administrate a composition for inhibiting expression of the following genes and/or an agent capable of inhibiting function of the protein.

Assignees

• Veraverse Co Ltd
• Univ Yonsei Iacf

Inventors

• Cheong Jae-Ho
• Kim Jae-Woo
• Fang Sungsoon
• Yoon Bo Kyung
• Kim Hyeonhui

Classifications

• A61K31/396

  having three-membered rings, e.g. aziridine · CPC title

• A61K31/4995

  Pyrazines or piperazines forming part of bridged ring systems · CPC title

• A61K31/501 Primary

  not condensed and containing further heterocyclic rings · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title